The effect of Tanacetum parthenium (L) Sch syrup on clinical manifestations of patients with COVID-19

The comparison of effectiveness of Tanacetum parthenium (L) Sch. syrups on clinical and paraclinical features of inpatients infected with 2019 novel coronavirus COVID-19, Parallel randomized trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180610040049N4

Enrollment

Registered

2020-04-03

Start date

2020-04-07

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Corona Virus. Coronavirus infection, unspecified

Interventions

Intervention 1: "Intervention group:" This group consumes the Trachyspermum copticum syrup. The total extract of this plant is used.The concentration of this syrup is 10% of the aqueous extract of Tan

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Having informed consent to participate in the study The definitive diagnosis of COVID-19 Failure to attend another clinical trial simultaneously

Exclusion criteria

Exclusion criteria: Patient's willingness to use other therapies Alzheimer's patients

Design outcomes

Primary

Measure	Time frame
Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.	—

Secondary

Measure	Time frame
The rate of lung inflammation. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: CT SCAN.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Shirvani

Ghoum University of Medical Sciences

bahramiazam26@gmail.com+98 25 3770 6470

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026